Document:

NBRV_Ex10_10

		

			Exhibit 10.10

		

		

			 

		

		

			Form of RSU Award Agreement for Executives (Share Withholding)

		

		

			 

		

		
			NABRIVA THERAPEUTICS PLC
		

		
			RESTRICTED SHARE UNIT AGREEMENT
		

		
			GRANTED UNDER 2017 SHARE INCENTIVE PLAN
		

		
			 
		

		
			This Restricted Share Unit Agreement (this “Agreement”) is made between Nabriva Therapeutics plc, a public limited company organized under the laws of Ireland (the “Company”), and the Participant pursuant to the 2017 Share Incentive Plan (the “Plan”).
		

		
			 
		

		
			NOTICE OF GRANT
		

		
			 
		

		
			I.          Participant Information
		

			
					
						 

					
					
						 

				
	
					
						Participant:

					
					
						 

				
	
					
						Participant Address:

					
					
						 

				

		
			 
		

		
			II.        Grant Information
		

			
					
						 

					
					
						 

				
	
					
						Grant Date:

					
					
						 

				
	
					
						Number of Restricted Share Units:

					
					
						 

				

		
			 
		

		
			III.       Vesting Table
		

			
					
						 

					
					
						 

				
	
					
						Vesting Date 

					
					
						Number of Restricted Share

					
						Units that Vest

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				

		
			 
		

		
			This Agreement includes this Notice of Grant and the following Exhibits and Schedules, which are expressly incorporated by reference in their entirety herein:
		

		
			 
		

		
			Exhibit A – General Terms and Conditions
		

		
			Exhibit B – Nabriva Therapeutics plc 2017 Share Incentive Plan
		

		
			Schedule 1 – Vesting Schedule
		

		
			Schedule 2 – Additional Terms and Conditions
		

		
			 
		

		
			IN WITNESS WHEREOF, the parties hereto have executed this Agreement.
		

		
			 
		

			
					
						NABRIVA THERAPEUTICS PLC

					
					
						PARTICIPANT

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						Name:

					
					
						 

				
	
					
						Title:

					
					
						Name:

				

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

			Form of RSU Award Agreement for Executives (Share Withholding)

		

		

			 

		

		

		
			 
		

		
			Restricted Share Unit Agreement
		

		
			2017 Share Incentive Plan
		

		
			EXHIBIT A
		

		
			GENERAL TERMS AND CONDITIONS
		

		
			For valuable consideration, receipt of which is acknowledged, the parties hereto agree as follows:
		

		
			1.         Award of Restricted Share Units.  This Agreement evidences the grant by the Company, on the grant date (the “Grant Date”) set forth in the Notice of Grant that forms part of this Agreement (the “Notice of Grant”), to the Participant, subject to the terms and conditions set forth in this Agreement and in the Company’s 2017 Share Incentive Plan (the “Plan”), of an award with respect to the number of restricted share units (the “RSUs”) set forth in the Notice of Grant.  Each RSU represents the right to receive one ordinary share of the Company (an “Ordinary Share”) upon vesting of the RSU, subject to the terms and conditions set forth herein.
		

		
			2.         Vesting.
		

		
			(a)        The RSUs shall vest in accordance with the Vesting Table set forth in the Notice of Grant.
		

		
			(b)        Upon the vesting of the RSUs, the Company will deliver to the Participant, for each RSU that becomes vested, one Ordinary Share, subject to the payment of any taxes pursuant to Section 4.  Each Ordinary Share will be delivered to the Participant as soon as practicable following each vesting date, but in any event within 30 days of such date.
		

		
			3.         Forfeiture of Unvested RSUs Upon Cessation of Service.
		

		
			In the event that the Participant ceases to perform services to the Company for any reason or no reason, with or without cause, all of the RSUs that are unvested as of the time of such cessation shall be forfeited immediately and automatically to the Company, without the payment of any consideration to the Participant, effective as of such cessation.  The Participant shall have no further rights with respect to the unvested RSUs or any Ordinary Shares that may have been issuable with respect thereto.  If the Participant provides services to a subsidiary of the Company, any references in this Agreement to provision of services to the Company shall instead be deemed to refer to service with such subsidiary.
		

		
			4.         Tax Matters.
		

		
			(a)        Acknowledgments; No Section 83(b) Election.  The Participant acknowledges that he or she is responsible for obtaining the advice of the Participant’s own tax advisors with respect to the award of RSUs and the Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items related to participation in the Plan and legally applicable to the Participant ("Tax-Related Items")
		

		
			
		

		
			

		 

		

			Form of RSU Award Agreement for Executives (Share Withholding)

		

		

			 

		

		

		
			 
		

		
			relating to the RSUs.  The Participant understands that the Participant (and not the Company) shall be responsible for the Participant’s Tax-Related Items that may arise in connection with the grant, vesting and/or settlement of the RSUs, the subsequent sale of Ordinary Shares acquired pursuant to such settlement and the receipt of dividends.  The Participant acknowledges that no election under Section 83(b) of the Internal Revenue Code, as amended, is available with respect to RSUs and that the Company is under no obligation to structure the terms of the grant or any aspect of the RSUs to reduce or eliminate the Participant's liability for Tax-Related Items or achieve any particular tax result. Further, if the Participant becomes subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable event, as applicable, the Participant acknowledges that the Company may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
		

		
			(b)        Withholding.  The Participant acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Participant any federal, state, local or other Tax-Related Items of any kind (including Tax-Related Items of jurisdictions outside the United States, as applicable) required by law to be withheld with respect to the RSUs.  The Participant may satisfy such Tax-Related Items by instructing the Company to withhold a number of Ordinary Shares having a fair market value (valued in the manner determined by (or in a manner approved by) the Board) on the applicable vesting date equal to the Tax-Related Items, based on minimum statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income. If the Participant does not instruct the Company to withhold Ordinary Shares to satisfy any applicable Tax-Related Items, then the Participant agrees that if under applicable law the Participant will owe Tax-Related Items at such time on any portion of the Award the Company shall be entitled to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following:
		

		
			(1)        immediate payment from the Participant of the amount to be withheld by the Company; or
		

		
			(2)        withholding from wages or other cash compensation otherwise paid to the Participant by the Company on the applicable vesting date.
		

		
			 
		

		
			The Company shall not deliver any Ordinary Shares to the Participant until it is satisfied that all required withholdings have been made and the Participant has complied with the above obligations in connection with Tax-Related Items.
		

		
			 
		

		
			5.         Transfer Restrictions; Clawback.
		

		
			(a)        The Participant shall not sell, assign, transfer, pledge, hypothecate or otherwise dispose of or encumber, by operation of law or otherwise (collectively “transfer”) any RSUs, or any interest therein. The Company shall not be required to treat as the owner of any RSUs or issue any Ordinary Shares to any transferee to whom such RSUs have been transferred in violation of any of the provisions of this Agreement.
		

		
			(b)        In accepting this award, the Participant agrees to be bound by any clawback policy that the Company may adopt in the future.
		

		
			
		

		
			

		 

		

			Form of RSU Award Agreement for Executives (Share Withholding)

		

		

			 

		

		

		
			 
		

		
			6.         Data Privacy.
		

		
			(a)        Consent. The Participant hereby acknowledges and consents to the collection, use, processing and/or transfer by the Company of Personal Data as defined and described in this Section 6.  The Participant is not obliged to consent, however a failure to provide consent, or the withdrawal of consent at any time, may impact the Participant’s ability to participate in the Plan. The Participant accepts that the consent provided pursuant to this Section 6 includes consent to any transfer of Personal Data throughout the world.
		

		
			(b)        Information Collected.  The Company and/or the Participant’s employer collects and maintains certain personal information about the Participant that may include name, home address and telephone number, date of birth, social security number or other government or employer-issued identification number, salary grade, hire data, salary, citizenship, job title, any Ordinary Shares of the Company, or details of all RSUs or any other entitlement to Ordinary Shares awarded, canceled, vested, or unvested (collectively “Personal Data”).
		

		
			(c)        Uses made of Data.  The Company may use, process and/or transfer Personal Data among other group companies to implement, administer and/or manage the Participant’s participation in the Plan. The Company may further use, process, analyze and/or transfer Personal Data for its overall administration, management and/or improvement of the Plan and/or to comply with any applicable laws and regulations. The Company maintains technical, administrative and physical safeguards designed to protect Personal Data.
		

		
			(d)        Disclosure of Data.  The Company may share and/or transfer Personal Data, in electronic or other format, to selected third parties including but not limited to the Plan’s service provider.  Such third parties assist in the implementation, administration and/or management of the Plan or the Participant’s participation in the Plan, for example to facilitate the holding of shares of stock on Participant’s behalf or to process the Participant’s election to deposit shares of stock acquired pursuant to the Plan with a broker or other third party. Third parties retained by the Company may use the Personal Data as authorized by the Company to provide the requested services in accordance with the requirements of data protection legislation. Third parties may be located throughout the world, including but not limited to the United States. Third parties often maintain their own published policies that describe their privacy and security practices. The Company is not responsible for the privacy or security practices of any third parties.
		

		
			(e)        Participant Rights.  The Participant may request access to, rectification, erasure, portability or restriction of their Personal Data, or object to the processing of their Personal Data at any time by contacting the Company and/or the Plan’s service provider. Participant shall have the right to obtain and reuse their Personal Data as provided to the Company. The Company will respond to any such request in writing, or orally if requested, as soon as practicable and in any event not more than one month after receipt of such request. The Company may request proof of identification to verify such a request.
		

		
			7.         Rights as a Shareholder.  The Participant shall have no rights as a shareholder of the Company with respect to any Ordinary Shares that may be issuable with respect to the RSUs until the issuance of the Ordinary Shares to the Participant following the vesting of the RSUs.
		

		
			
		

		
			

		 

		

			Form of RSU Award Agreement for Executives (Share Withholding)

		

		

			 

		

		

		
			 
		

		
			8.         Provisions of the Plan. This Agreement is subject to the provisions of the Plan (including the provisions relating to amendments to the Plan), a copy of which is attached hereto as Exhibit B.
		

		
			 
		

		
			9.         Miscellaneous.
		

		
			(a)        No Right to Continued Service/Compensation for Loss.  The Participant acknowledges and agrees that, notwithstanding the fact that the vesting of the RSUs is contingent upon his or her continued service to the Company, this Agreement does not constitute an express or implied promise of continued service relationship with the Participant or confer upon the Participant any rights with respect to a continued service relationship with the Company. Under no circumstances will the Participant ceasing to be an employee of the Company be entitled to compensation for any loss of any right or benefit or prospective right or benefit under the Plan which the Participant might otherwise have enjoyed whether such compensation is claimed by way of damages for wrongful dismissal or other breach of contract or by way of compensation for loss of office or otherwise howsoever.
		

		
			(b)        Section 409A.  The RSUs awarded pursuant to this Agreement are intended to be exempt from or comply with the requirements of Section 409A of the Internal Revenue Code and the Treasury Regulations issued thereunder (“Section 409A”).  The delivery of Ordinary Shares on the vesting of the RSUs may not be accelerated or deferred unless permitted or required by Section 409A.
		

		
			(c)        Participant’s Acknowledgements.  The Participant acknowledges that he or she: (i) has read this Agreement; (ii) has been represented in the preparation, negotiation and execution of this Agreement by legal counsel of the Participant’s own choice or has voluntarily declined to seek such counsel; (iii) understands the terms and consequences of this Agreement; and (iv) is fully aware of the legal and binding effect of this Agreement.
		

		
			(d)        Governing Law.  This Agreement shall be governed by, except to the extent preempted by other applicable laws (1) with respect to the corporate law requirements applicable to the Company, the validity and authorization of the issuance of Ordinary Shares under the Plan and similar matters, the laws of Ireland (without reference to conflict of law principles thereof) and (2) with respect to all other matters relating to the Plan and Awards, the laws of the State of Delaware, excluding choice-of-law principles of the law of that state.
		

		
			[Remainder of Page Intentionally Left Blank]
		

		
			 
		

		
			
		

		
			

		 

		

			Form of RSU Award Agreement for Executives (Share Withholding)

		

		

			 

		

		

		
			 
		

		
			Schedule 1
		

		
			 
		

		
			Vesting Schedule
		

		
			 
		

		
			
		

		
			

		 

		

			Form of RSU Award Agreement for Executives (Share Withholding)

		

		

			 

		

		

		
			 
		

		
			Schedule 2
		

		
			 
		

		
			Additional terms to Restricted Share Unit Award Agreement
		

		
			 
		

		
			Terms and Conditions
		

		
			This Schedule (the “Schedule”) includes additional terms and conditions that govern the RSUs granted to you under the Plan if you reside in one of the countries listed below. Certain capitalized terms used but not defined in this Schedule have the meanings set forth in the Plan and/or the Agreement.
		

		
			Notifications
		

		
			This Schedule also includes country-specific information of which you should be aware with respect to your participation in the Plan.  The information is based on the securities, exchange control and other laws in effect in the respective countries as of January 2018.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that you do not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that you vest in the RSUs and Ordinary Shares are issued to you or the shares issued upon vesting of the RSUs are sold.
		

		
			In addition, the information is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result.  Accordingly, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your particular situation.  Finally, please note that if you are a citizen or resident of a country other than the country in which you are currently working, or transfers employment after grant, the information contained in the Schedule may not be applicable.
		

		
			Ireland
		

		
			Notifications
		

		
			Director Notification Obligation. If you are a director, shadow director or secretary of the Company or an Irish subsidiary or affiliate of the Company, and you acquire or dispose of an interest under this Agreement comprising more than 1% of the share capital in the Company, you must notify the entity in which you hold that office (whether the Company itself or an Irish subsidiary or affiliate of the Company) in writing within five business days of receiving or disposing of an interest in the Company, or within five business days of becoming aware of the event giving rise to the notification requirement or within five days of becoming a director or secretary if such an interest exists at the time. This notification requirement also applies with respect to the interests of a spouse or children under the age of 18 (whose interests will be attributed to the director, shadow director or secretary).NBRV_Ex10_40

		
			Exhibit 10.40
		

		
			SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT
		

		
			THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of January 8, 2020 (the “Amendment Effective Date”), is made among Nabriva Therapeutics Public Limited Company, a public limited company incorporated in Ireland under registration number 599588 and having its registered office at 25-28 North Wall Quay, Dublin 1, Ireland (“Parent”), Nabriva Therapeutics Ireland Designated Activity Company, a designated activity company incorporated in Ireland under registration number 612454 and having its registered office at Suite 510, Regus Dublin Airport, Skybridge House, Dublin Airport, Swords, County Dublin, Ireland (“Nabriva Ireland”; together with Parent, individually and collectively, jointly and severally, the “Borrower”), Nabriva Therapeutics GmbH, a limited liability company (Gesellschaft mit beschränkter Haftung) incorporated under the laws of the Republic of Austria, having its seat in Vienna and its registered address at Leberstraße 20, 1110 Vienna, and registered with the companies’ register (Firmenbuch) of the commercial court of Vienna (Handelsgericht Wien) under registration number 269261 y (“Nabriva Austria”), Nabriva Therapeutics US, Inc., a Delaware corporation (“Nabriva US”), Zavante Therapeutics, Inc., a Delaware corporation (“Zavante”; together with Nabriva Austria and Nabriva US, collectively referred to as the “Guarantors” and each, a “Guarantor”), Hercules Capital, Inc. , a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and Lender (in such capacity, together with its successors and assigns in such capacity, “Agent”).
		

		
			The Loan Parties, the Lenders and Agent are parties to a Loan and Security Agreement dated as of December 20, 2018, as amended by the First Amendment to Loan and Security Agreement dated September 26, 2019  (and as further amended, restated or modified from time to time, the “Loan and Security Agreement”).  Loan Parties have requested that the Lenders agree to certain consents and amendments to the Loan and Security Agreement.  The Lenders have agreed to such request, subject to the terms and conditions hereof.
		

		
			Accordingly, the parties hereto agree as follows:
		

		
			SECTION 1        Definitions; Interpretation.
		

		
			(a)          Terms Defined in Loan and Security Agreement.  All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan and Security Agreement.
		

		
			(b)          Interpretation.  The rules of interpretation set forth in the last paragraph of Section 1.1 of the Loan and Security Agreement shall be applicable to this Amendment and are incorporated herein by this reference.
		

		
			SECTION 2        Amendments to the Loan and Security Agreement.
		

		
			(a)          The Loan and Security Agreement shall be amended as follows effective as of the Amendment Effective Date:
		

		
			(i)           New Definitions.  The following definitions are added to Section 1.1 in their proper alphabetical order:
		

		
			“Second Amendment” means that certain Second Amendment to Loan and Security Agreement, dated as of the Second Amendment Effective Date, by and among Borrower, the Guarantors, Agent and the lenders party thereto.
		

		
			“Second Amendment Effective Date” means January 8, 2020.
		

		
			(ii)          Section 7.12(b).  Section 7.12(b) is hereby amended and restated as follows:
		

		
			(b)          The Loan Parties shall be required to hold, in US Dollars, an amount of Unrestricted Cash in Deposit Accounts in the United States, Ireland and Luxembourg with respect to which Agent has an Account Control Agreement or a Foreign Account Pledge Agreement equal
		

		
			
		

		
			

		 

		

			1

		

		

		
			to the lesser of (i) 120% of the outstanding Secured Obligations, and (ii) 75% of all Unrestricted Cash (excluding amounts held in Excluded Accounts) of Parent and its Subsidiaries.
		

		
			(iii)         Section 7.21(a).  Section 7.21(a) is hereby amended and restated as follows:
		

		
			(a)          Minimum Cash. At all times, the Loan Parties shall be required to maintain Unrestricted Cash in Deposit Accounts held in the United States and Ireland in an amount greater than or equal to Ten Million US Dollars ($10,000,000) plus the amount of the Loan Parties’ accounts payable under GAAP not paid after the 90th day following the invoice date for such accounts payable.
		

		
			(b)          Compliance Certificate. Exhibit F of the Loan and Security Agreement, the Compliance Certificate, is hereby amended and restated in its entirety as set forth in Annex A attached hereto.
		

		
			(c)          References Within Loan and Security Agreement.  Each reference in the Loan and Security Agreement to “this Agreement” and the words “hereof,” “herein,” “hereunder,” or words of like import, shall mean and be a reference to the Loan and Security Agreement as amended by this Amendment.
		

		
			SECTION 3        Conditions of Effectiveness.  The effectiveness of Section 2 of this Amendment shall be subject to the satisfaction of each of the following conditions precedent:
		

		
			(a)          Fees and Expenses.  The Loan Parties shall have paid (i) all invoiced costs and expenses then due under the Loan Documents, and (ii) all other invoiced fees, costs and expenses, if any, due and payable as of the Amendment Effective Date under the Loan and Security Agreement.
		

		
			(b)          This Amendment.  Agent shall have received this Amendment, executed by Agent, the Lenders and the Loan Parties.
		

		
			(c)          Representations and Warranties; No Default.  On the Amendment Effective Date, after giving effect to the amendment of the Loan and Security Agreement contemplated hereby:
		

		
			(i)           The representations and warranties contained in Section 4 shall be true and correct on and as of the Amendment Effective Date as though made on and as of such date; and
		

		
			(ii)          There exist no Events of Default or events that with the passage of time would result in an Event of Default.
		

		
			SECTION 4        Representations and Warranties.  To induce the Lenders to enter into this Amendment, Each Loan Party hereby confirm, as of the date hereof, (a) that the representations and warranties made by it in Section 6 of the Loan and Security Agreement and in the other Loan Documents are true and correct in all material respects, except to the extent such representations and warranties expressly relate to an earlier date; (b) that there has not been and there does not exist a Material Adverse Effect; (c) that the information included in the Perfection Certificate delivered to Agent on the Closing Date remains true and correct; (d) Lender has and shall continue to have valid, enforceable and perfected first-priority liens, on and security interests in the Collateral and all other collateral heretofore granted by such Loan Party to Lender, pursuant to the Loan Documents or otherwise granted to or held by Lender; (e) the agreements and obligations of such Loan Party contained in the Loan Documents and in this Amendment constitute the legal, valid and binding obligations of such Loan Party, enforceable against such Loan Party in accordance with their respective terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws of general application affecting the enforcement of creditors’ rights or by the application of general principles of equity; and (f) the execution, delivery and performance of this Amendment by such Loan Party will not violate any law, rule, regulation, order, contractual obligation or organizational document of such Loan Party and will not result in, or require, the creation or imposition of any lien, claim or encumbrance of any kind on any of its properties or revenues.  For the purposes of this Section 4, each reference in Section 6 of the Loan and Security Agreement to “this Agreement,” and the words “hereof,” “herein,” “hereunder,” or words of like import in such Section, shall mean and be a reference to the Loan and Security Agreement as amended by this Amendment.
		

		
			
		

		
			

		 

		

			2

		

		

		
			SECTION 5        Miscellaneous.
		

		
			(a)          Consent. Agent hereby consents to the actual Net Product Revenue recognized by Parent during the month of September 2019 to apply to the month of October 2019 for purposes of Section 7.21(b)(i) of the Loan Agreement.
		

		
			(b)          Loan Documents Otherwise Not Affected; Reaffirmation; No Novation.
		

		
			(i)           Except as expressly amended pursuant hereto or referenced herein, the Loan and Security Agreement and the other Loan Documents shall remain unchanged and in full force and effect and are hereby ratified and confirmed in all respects.  The Lenders’ and Agent’s execution and delivery of, or acceptance of, this Amendment shall not be deemed to create a course of dealing or otherwise create any express or implied duty by any of them to provide any other or further amendments, consents or waivers in the future.
		

		
			(ii)          Each Loan Party hereby expressly (1) reaffirms, ratifies and confirms its Obligations under the Loan Agreement and the other Loan Documents, (2) reaffirms, ratifies and confirms the grant of security under Section 3.1 of the Loan and Security Agreement, (3) reaffirms that such grant of security in the Collateral secures all Obligations under the Loan and Security Agreement, and with effect from (and including) the Amendment Effective Date, such grant of security in the Collateral: (x) remains in full force and effect notwithstanding the amendments expressly referenced herein; and (y) secures all Obligations under the Loan and Security Agreement, as amended by this Amendment, and the other Loan Documents, (4) agrees that this Amendment shall be a “Loan Document” under the Loan Agreement and (5) agrees that the Loan Agreement and each other Loan Document shall remain in full force and effect following any action contemplated in connection herewith.
		

		
			(iii)         This Amendment is not a novation and the terms and conditions of this Amendment shall be in addition to and supplemental to all terms and conditions set forth in the Loan Documents. Nothing in this Amendment is intended, or shall be construed, to constitute an accord and satisfaction of any Loan Party’s Secured Obligations under or in connection with the Loan and Security Agreement and any other Loan Document or to modify, affect or impair the perfection or continuity of Agent’s security interest in, (on behalf of itself and the Lenders) security titles to or other liens on any Collateral for the Secured Obligations.
		

		
			(c)          Conditions.  For purposes of determining compliance with the conditions specified in Section 3, each Lender that has signed this Amendment shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless Agent shall have received notice from such Lender prior to the Amendment Effective Date specifying its objection thereto.
		

		
			(d)          Release.  In consideration of the agreements of Agent and each Lender contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Loan Party, on behalf of itself and its successors, assigns, and other legal representatives, hereby fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges Agent and each Lender, and its successors and assigns, and its present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Agent, Lenders and all such other persons being hereinafter referred to collectively as the “Releasees” and individually as a “Releasee”), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Borrower, or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment for or on account of, or in relation to, or in any way in connection with the Loan Agreement, or any of the other Loan Documents or transactions thereunder or related thereto.  Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.  Borrower agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above.
		

		
			
		

		
			

		 

		

			3

		

		

		
			(e)          No Reliance.  Borrower hereby acknowledges and confirms to Agent and the Lenders that Borrower is executing this Amendment on the basis of its own investigation and for its own reasons without reliance upon any agreement, representation, understanding or communication by or on behalf of any other Person.
		

		
			(f)           Binding Effect.  This Amendment binds and is for the benefit of the successors and permitted assigns of each party.
		

		
			(g)          Governing Law.  THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL IN ALL RESPECTS BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF ANY LAWS OTHER THAN THE LAWS OF THE STATE OF NEW YORK), INCLUDING ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE, REGARDLESS OF THE LOCATION OF THE COLLATERAL.
		

		
			(h)          Complete Agreement; Amendments.  This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements with respect to such subject matter.  All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents.
		

		
			(i)           Severability of Provisions.  Each provision of this Amendment is severable from every other provision in determining the enforceability of any provision.
		

		
			(j)           Counterparts.  This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Amendment.  Delivery of an executed counterpart of a signature page of this Amendment by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.
		

		
			(k)          Loan Documents. This Amendment and the documents related thereto shall constitute Loan Documents.
		

		
			[Balance of Page Intentionally Left Blank; Signature Pages Follow]
		

		
			 
		

		
			 
		

		
			

		 

		

			4

		

		

		
			IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as of the date first above written.
		

		
			BORROWER:
		

		
			Nabriva Therapeutics Public Limited Company
		

		
			GIVEN under the COMMON SEAL of
		

		
			NABRIVA THERAPEUTICS PUBLIC LIMITED COMPANY
		

		
			and DELIVERED as a DEED:
		

			
					
						 

					
					
						 

				
	
					
						/s/ Gary Sender

					
					
						 

				
	
					
						Gary Sender

					
					
						 

				
	
					
						Authorised Signatory

					
					
						 

				

		
			 
		

		
			
		

		
			

		 

		

			 

		

		

		
			Nabriva Therapeutics Ireland Designated Activity Company
		

		
			SIGNED AND DELIVERED as a Deed
		

		
			for and on behalf of
		

		
			NABRIVA THERAPEUTICS IRELAND DESIGNATED ACTIVITY COMPANY
		

		
			by its lawfully appointed attorney
		

		
			GARY SENDER
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						    

					
					
						/s/ Gary Sender

				
	
					
						 

					
					
						 

					
					
						Signature of Attorney

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						in the presence of:

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						/s/ Chris Naftzger

					
					
						 

					
					
						 

				
	
					
						Signature of Witness

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						Attorney

					
					
						 

					
					
						 

				
	
					
						Occupation of Witness

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						1305 Homestead Lane, Lancaster PA 17663

					
					
						 

					
					
						 

				
	
					
						Address of Witness

					
					
						 

					
					
						 

				

		
			 
		

		
			
		

		

		 

		

			 

		

	
					
						

					
						 

					
					
						    

					
					
						GUARANTORS:

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						NABRIVA THERAPEUTICS GMBH

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						By:

					
					
						/s/ Gary Sender

				
	
					
						 

					
					
						 

					
					
						Name:

					
					
						Gary Sender

				
	
					
						 

					
					
						 

					
					
						Title:

					
					
						CFO

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						NABRIVA THERAPEUTICS US, INC.

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						By:

					
					
						/s/ Gary Sender

				
	
					
						 

					
					
						 

					
					
						Name:

					
					
						Gary Sender

				
	
					
						 

					
					
						 

					
					
						Title:

					
					
						CFO

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						ZAVANTE THERAPEUTICS, INC.

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						By:

					
					
						/s/ Gary Sender

				
	
					
						 

					
					
						 

					
					
						Name:

					
					
						Gary Sender

				
	
					
						 

					
					
						 

					
					
						Title:

					
					
						CFO

				

		
			 
		

		
			
		

		

		 

		

			 

		

	
					
						

					
						 

					
					
						    

					
					
						AGENT:

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						HERCULES CAPITAL, INC.,

				
	
					
						 

					
					
						 

					
					
						as Agent

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						By:

					
					
						/s/ Jennifer Choe

				
	
					
						 

					
					
						 

					
					
						Name: Jennifer Choe

				
	
					
						 

					
					
						 

					
					
						Title: Assistant General Counsel

				

		
			 
		

		
			
		

		

		 

		

			 

		

	
					
						

					
						 

					
					
						    

					
					
						LENDER:

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						HERCULES CAPITAL, INC.,

				
	
					
						 

					
					
						 

					
					
						as Lender

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						By:

					
					
						/s/ Jennifer Choe

				
	
					
						 

					
					
						 

					
					
						Name: Jennifer Choe

				
	
					
						 

					
					
						 

					
					
						Title: Assistant General Counsel

				

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

			 

		

		

		
			ANNEX A
		

		
			EXHIBIT F
		

		
			COMPLIANCE CERTIFICATE
		

		
			[_____________ __, 20__]
		

		
			Hercules Capital, Inc. (as “Agent”)
400 Hamilton Avenue, Suite 310
Palo Alto, CA 94301
		

		
			Reference is made to that certain Loan and Security Agreement dated December 20, 2018 and the Loan Documents (as defined therein) entered into in connection with such Loan and Security Agreement all as may be amended from time to time (hereinafter referred to collectively as the “Loan Agreement”) by and among the lenders from time to time party thereto (collectively, the “Lender”), Hercules Capital, Inc., as agent for the Lender (the “Agent”), Nabriva Therapeutics Public Limited Company,  a public limited company incorporated in Ireland under registration number 599588 and having its registered office at 25-28 North Wall Quay, Dublin 1, Ireland (“Parent”), Nabriva Therapeutics Ireland Designated Activity Company,  a designated activity company incorporated in Ireland under registration number 612454 and having its registered office at Suite 510, Regus Dublin Airport, Skybridge House, Dublin Airport, Swords, County Dublin, Ireland (“Nabriva Ireland”; together with Parent, individually and collectively, jointly and severally, the “Borrower”), Nabriva Therapeutics GmbH, a limited liability company (Gesellschaft mit beschränkter Haftung) incorporated under the laws of the Republic of Austria, having its seat in Vienna and its registered address at Leberstraße 20, 1110 Vienna, and registered with the companies’ register (Firmenbuch) of the commercial court of Vienna (Handelsgericht Wien) under registration number 269261 y (“Nabriva Austria”), Nabriva Therapeutics US, Inc., a Delaware corporation (“Nabriva US”), and Zavante Therapeutics, Inc., a Delaware corporation (“Zavante”), and each of their Subsidiaries from time to time party thereto (together with Nabriva Austria, and Nabriva US, collectively referred to as the “Guarantors” and each, a “Guarantor”).  All capitalized terms not defined herein shall have the same meaning as defined in the Loan Agreement.
		

		
			The undersigned is an Officer of the Parent, knowledgeable of all Loan Party financial matters, and is authorized to provide certification of information regarding the Loan Parties; hereby certifies, in such capacity, that in accordance with the terms and conditions of the Loan Agreement, the Loan Parties are in compliance for the period ending ___________ of all covenants, conditions and terms therein and hereby reaffirms that all representations and warranties contained therein are true and correct in all material respects, other than as disclosed in this Compliance Certificate, on and as of the date of this Compliance Certificate with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, after giving effect in all cases to any standard(s) of materiality contained in the Loan Agreement as to such representations and warranties.  Attached are the required documents supporting the above certification.  The undersigned further certifies that these are prepared in accordance with GAAP (except for the absence of footnotes with respect to unaudited financial statement and subject to normal year-end adjustments) and are consistent from one period to the next except as explained below.
		

		
			
		

		

		 

		

			10

		

	
					
						

					
						REPORTING REQUIREMENT

					
					
						REQUIRED

					
					
						CHECK IF ATTACHED

				
	
					
						Interim Financial Statements 

					
					
						Monthly within 30 days, as applicable

					
					
						 

				
	
					
						Interim Financial Statements 

					
					
						Quarterly within 45 or 60 days, as applicable 

					
					
						 

				
	
					
						Audited Financial Statements 

					
					
						FYE within 90 days 

					
					
						 

				
	
					
						Accounts Receivable and Accounts Payable (7.1(e))

					
					
						Monthly within 30 days

					
					
						 

				
	
					
						Projections (7.1(g))

					
					
						FYE within 75 days

					
					
						 

				

		
			 
		

		
			Note: Section 7.12(b), 7.21(a), and 7.21(b) below can be completed through the use of an attached Excel-based spreadsheet (which is deemed part of this Compliance Certificate). Check if a supporting spreadsheet is attached:  __ Yes; __ No
		

		
			7.12(b) – Cash Management
		

		
			(a) The amount of Unrestricted Cash in the United States, Ireland and Luxembourg as of the date hereof: $______________
		

		
			(b) outstanding Secured Obligations: $______________ multiplied by 1.20 = $_______________
		

		
			(c) all Cash (excluding amounts held in Excluded Accounts) of Parent and its consolidated Subsidiaries: $_______________ multiplied by 0.75 = $_________________
		

		
			(d) Is the amount reported in clause (a) greater than or equal to the lesser of (b) and (c)? __ Yes; __ No
		

		
			If No: not in compliance
		

		
			7.21(a) – Minimum Cash
		

		
			(a) The amount of Unrestricted Cash in the United States and Ireland as of the date hereof: $_________________
		

		
			(b) The amount of the Loan Parties’ accounts payable under GAAP not paid after the 90th day following the invoice date for such accounts payable $_________________
		

		
			
		

		
			

		 

		

			11

		

		

		
			(c) Clause (b)  plus $10,000,000 is $_________________
		

		
			(d) Is the amount in clause (a) equal to or greater than the amount in clause (c)? __ Yes; __ No
		

		
			If No: not in compliance.
		

		
			7.21(b) – Performance Covenant
		

		
			(a) Has the Performance Covenant Trigger Date passed? __ Yes; __ No
		

		
			If Yes:
		

		
			(i) Trailing six month Net Product Revenue: $_________________
		

		
			(ii) 80% of forecasted trailing six month Net Product Revenue in the Forecast: $_________________
		

		
			(iii) Is clause (i) greater than or equal to clause (ii)? __ Yes; __ No
		

		
			If Yes: in compliance.
		

		
			If No:
		

		
			(iv) The amount of Unrestricted Cash as of the date of this Compliance Certificate: $_________________
		

		
			(v) 80% of Eligible Accounts as of the date of this Compliance Certificate: $_________________
		

		
			(vi) Clause (iv) plus clause (v) is: $_________________
		

		
			(vii) The amount of outstanding Advances plus the amount of accounts payable under GAAP not paid after the 90th day following the invoice date for such accounts payable as of the date of this Compliance Certificate is:  $_________________
		

		
			(viii) Are both of the following true: (a) clause is (vi) greater than or equal to clause (vii), and (b) the amount in clause (iv) is greater than or equal to $40,000,000?  __ Yes; __ No
		

		
			If No: not in compliance.
		

		
			If Yes: in compliance.
		

		
			
		

		
			

		 

		

			12

		

		

		
			Section 7.19 – Intellectual Property
		

		
			(a) Has any Loan Party filed or obtained any new Patent, registered Trademark, or registered Copyright since the last reported period? __ Yes; __ No
		

		
			If yes: Borrower shall supplement such intellectual property security agreements and or other documents as needed to maintain a first priority perfected security interest in favor of Agent within 90 days of the date hereof.
		

		
			(b) Is any utilized Intellectual Property not registered in the current legal name of Nabriva Austria as the owner of such Intellectual Property in the registry in the United States, Ireland and Austria?  __ Yes (not in compliance); __ No (in compliance)
		

		
			(c) Has Nabriva Austria filed corrective filings in the United States, Ireland or Austria to updated its name from Nabriva Therapeutics AG to Nabriva Therapeutics GmbH since the last reported period? __ Yes; __ No
		

		
			If yes: Borrower shall supplement such intellectual property security agreements and or other documents as needed to maintain a first priority perfected security interest in favor of Agent within 90 days of the date hereof.
		

		
			If yes: the IP Security Agreement, Debenture, and/or IP Security Agreement in relation to Nabriva Austria, as applicable, shall be supplemented within 90 days of the date hereof.
		

		
			The undersigned hereby also confirms the below disclosed accounts represent all depository accounts and securities accounts presently open in the name of each Loan Party or and their Subsidiaries, as applicable.
		

			
					
						 

					
					
						 

					
					
						Depository
AC #

					
					
						Financial
Institution

					
					
						Account
Type
(Depository /
Securities)

					
					
						Last
Month
Ending
Account
Balance

					
					
						Purpose
of
Account

					
					
						New
Account
Since
Last
Reporting
Period?

				
	
					
						BORROWER
Name/Address:

					
					
						 

				
	
					
						 

					
					
						1

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						2

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						3

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						4

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						5

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						6

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						7

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				

		
			 
		

		
			
		

		

		 

		

			13

		

	
					
						

					
						 

				
	
					
						BORROWER SUBSIDIARY
Name/Address

					
					
						 

				
	
					
						 

					
					
						1

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						2

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						3

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						4

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						5

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						6

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						7

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				

		
			 
		

		
			 
		

			
					
						 

					
					
						Very Truly Yours,

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						[                                                          ],

				
	
					
						 

					
					
						on behalf of itself and its Subsidiaries

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						Name:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						Its:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						Date Submitted:

					
					
						 

				

		
			 
		

		 

		

			14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]